HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative findings, pathological stage PSA recurrence in men with prostate cancer incidentally detected at radical cystectomy: our experience in 242 cases.

AbstractPURPOSE:
Preoperative findings, pathological stage PSA recurrence in patients with prostate cancer incidentally detected (iPCa) at radical cystectomy (RCP) were prospectively evaluated.
METHODS:
From July 2000 to July 2013, 242 men 71 years old (median) underwent RCP; preoperatively, all patients underwent digital rectal examination (DRE), total and free/total PSA. The bladder was totally examined; moreover, the prostate gland was step-sectioned at 4-mm intervals. The incidence of iPCa that fulfilled criteria for clinically significant iPCa was recorded: tumor volume ≥0.5 mL, Gleason grade ≥4, extracapsular extension, seminal vesicle invasion, lymph node metastasis or positive surgical margins. In the presence of iPCa, the patients underwent PSA evaluation during the follow-up and recurrence was defined as two subsequent rises >0.2 ng/mL.
RESULTS:
Among the 50 (20.6%) out of 242 patients submitted to RCP, an iPCa was found and 18 (36%) of them met criteria for insignificant iPCa; moreover, 30% of the patients had apex involvement. Median total PSA and PSA F/T values were not significantly different in the presence versus the absence of iPCa (2.6 vs 2.7 ng/mL and 26 vs 27%; p > 0.05) and between significant versus insignificant iPCa (p > 0.05). None of the patients during the follow-up (median 58 months; range 6-102 months) had PSA recurrence.
CONCLUSIONS:
PSA and PSA F/T values are provided for poor accuracy in distinguishing preoperatively significant from insignificant iPCa; however, the life expectancy of the patients is dramatically influenced by bladder cancer pTN (in our series, none developed PSA failure). In younger men in whom a prostate-sparing cystectomy could be proposed, an accurate preoperative evaluation should be mandatory to rule out significant iPCa at the risk of apex involvement (in our series equal to 30% of the cases).
AuthorsPietro Pepe, Filippo Fraggetta, Antonio Galia, Paolo Panella, Michele Pennisi, Maurizio Colecchia, Francesco Aragona
JournalInternational urology and nephrology (Int Urol Nephrol) Vol. 46 Issue 7 Pg. 1325-8 (Jul 2014) ISSN: 1573-2584 [Electronic] Netherlands
PMID24488687 (Publication Type: Journal Article)
Chemical References
  • Prostate-Specific Antigen
Topics
  • Aged
  • Aged, 80 and over
  • Cystectomy
  • Humans
  • Incidental Findings
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasms, Multiple Primary (epidemiology, surgery)
  • Preoperative Period
  • Prospective Studies
  • Prostate-Specific Antigen (blood)
  • Prostatic Neoplasms (blood, pathology)
  • Urinary Bladder Neoplasms (epidemiology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: